Piper Sandler Maintains Overweight on Globus Medical, Lowers Price Target to $100
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
Piper Sandler analyst Matt O'Brien maintains Globus Medical (NYSE:GMED) with a Overweight and lowers the price target from $115 to $100.
Piper Sandler analyst Matt O'Brien maintains Globus Medical (NYSE:GMED) with a Overweight and lowers the price target from $115 to $100.